Sanofi Pasteur rolls out Quadracel in the U.S. to take on GSK's Kinrix

Sanofi Pasteur
Sanofi Pasteur’s DTaP-IPV vaccine Quadracel, a competitor to GSK's Kinrix, rolled out in the U.S.

After winning FDA approval in May 2015, Sanofi Pasteur’s DTaP-IPV vaccine Quadracel is finally available in the U.S. and ready to challenge GlaxoSmithKline’s Kinrix.

The vaccine is designed to protect against diphtheria, tetanus, acellular pertussis (DTaP) and poliovirus in children 4 through 6 years old.

The CDC recommended that children in the age range receive a fifth dose of the DTaP vaccine and a fourth dose of inactivated poliovirus (IPV) vaccine; Sanofi’s Quadracel combines those in a single shot.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Fewer doses means more convenience for families, potentially increasing vaccination rates, said Dr. Michael Smith, Associate Professor of Pediatrics at the University of Louisville School of Medicine, in a press release

Quadracel will directly compete with GlaxoSmithKline’s Kinrix, another DTaP-IPV vaccine that was approved in 2008 as a combo shot for the fifth DTaP and fourth IPV booster. The GSK version is currently listed with a $48.6 per dose price tag for private buyers, according to the CDC.

The two companies have long been wrestling each other in DTaP pediatric vaccines. Besides its own DTaP-only vaccine, GSK also has Pediarix, a DTaP-Hep B-IPV combo shot approved in 2002, while the French company has Pentacel, a DTaP-IPV-Hib option approved in 2008.

In a September 2016 report, EvaluatePharma predicted Pentacel would be the fourth best-selling vaccine in 2022, with Pediarix trailing right behind. The report put their sales numbers that year at $1.75 billion and $1.32 billion respectively.

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.